Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II maintenance homoharringtonine in chronic myeloid leukemia
2005-000814-11Phase 2Completed
- Sponsor
- Stragen
- Start
- Sep 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of homoharringtonine in chronic myelogenous leukemia (CML), sponsored by Stragen. Primary endpoints: Hematologic response rate and duration and Time to disease progression. Started Sep 2005; status: completed.
02
Drugs
homoharringtonine
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2005-000814-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000814-11.